MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

被引：1

作者：

O'Connor, P ^{[1
]}

Fleming, P ^{[1
]}

Gray, T ^{[1
]}

Jacobs, L ^{[1
]}

Miller, C ^{[1
]}

Munschauer, F ^{[1
]}

Kinkel, RP ^{[1
]}

Bolibrush, D ^{[1
]}

Cohen, J ^{[1
]}

Freedman, M ^{[1
]}

Webb, U ^{[1
]}

Rabinowicz, H ^{[1
]}

Metz, LM ^{[1
]}

Patry, D ^{[1
]}

Yeung, M ^{[1
]}

Peters, S ^{[1
]}

Hashimoto, S ^{[1
]}

Morrison, W ^{[1
]}

Oger, J ^{[1
]}

Panitch, H ^{[1
]}

Costello, K ^{[1
]}

Bever, C ^{[1
]}

Stuart, W ^{[1
]}

Court, D ^{[1
]}

Stuart, D ^{[1
]}

Tornatore, C ^{[1
]}

Bartlett, D ^{[1
]}

Richert, J ^{[1
]}

Duquette, P ^{[1
]}

Dubois, R ^{[1
]}

Bernier, G ^{[1
]}

Scott, T ^{[1
]}

Pappert, L ^{[1
]}

Brillman, J ^{[1
]}

Felton, W ^{[1
]}

Anderson, T ^{[1
]}

Astruc, J ^{[1
]}

Rose, J ^{[1
]}

Kline, J ^{[1
]}

Burns, J ^{[1
]}

Murray, T ^{[1
]}

Weldon, P ^{[1
]}

Bhan, V ^{[1
]}

Maxner, CE ^{[1
]}

Wall, M ^{[1
]}

Vining, L ^{[1
]}

Grabowski, T ^{[1
]}

Apatoff, B ^{[1
]}

Orapello, C ^{[1
]}

Friedman, J ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA

来源：

NEUROLOGY | 2002年 / 59卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

引用

页码：998 / 1005

页数：8

共 50 条

[1] MRI predictors of clinically definite MS based on analyses of placebo patients from the CHAMPS trial
Simon, JH
NEUROLOGY, 2002, 58 (07) : A502 - A503
[2] Diagnostic MRI criteria: Prediction of conversion to clinically definite MS
Barkhof, F
Filippi, M
Comi, G
NEUROLOGY, 2002, 58 (07) : A157 - A157
[3] Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
Zivadinov, Robert
Dwyer, Michael G.
Carl, Ellen
Poole, Elizabeth M.
Cavalier, Steve
Briassouli, Paraskevi
Bergsland, Niels
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
[4] A profile of patients at high risk for the development of clinically definite MS (CDMS): The first report of the CHAMPS study
Jacobs, LD
Beck, RW
Brownscheidle, CM
Kinkel, RP
Miller, AE
Murray, TJ
Simon, JH
Blanchard, NL
Lloyd, KJ
Sandrock, AW
Simonian, NA
NEUROLOGY, 1999, 52 (06) : A495 - A495
[5] MRI indices as predictors of clinically definite multiple sclerosis development in patients with a clinically isolated syndrome
Myalovitska, O.
Nour, S. Sepehri
Lobanova, I.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 168 - 168
[6] Smoking is a risk factor for early conversion to clinically definite multiple sclerosis
Di Pauli, F.
Reindl, M.
Ehling, R.
Schautzer, F.
Gneiss, C.
Lutterotti, A.
O'Reilly, E. J.
Munger, K. L.
Deisenhammer, F.
Ascherio, A.
Berger, T.
MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (08) : 1026 - 1030
[7] Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis
Swanton, J. K.
Fernando, K. T.
Dalton, C. M.
Miszkiel, K. A.
Altmann, D. R.
Plant, G. T.
Thompson, A. J.
Miller, D. H.
MULTIPLE SCLEROSIS, 2010, 16 (02): : 156 - 165
[8] Baseline variables predictive of conversion from possible to clinically definite MS: ETOMS results
Martinelli-Boneschi, F
Hartung, HP
Sorensen, PS
Edan, G
Fernandez, O
Durelli, L
Roveris, M
Seeldrayers, P
Barkhof, F
Filippi, M
Hommes, O
Comi, G
NEUROLOGY, 2002, 58 (07) : A504 - A504
[9] Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
Barkhof, F
Filippi, M
Miller, DH
Scheltens, P
Campi, A
Polman, CH
Comi, G
Ader, HJ
Losseff, N
Valk, J
BRAIN, 1997, 120 : 2059 - 2069
[10] MRI-Only Conversion to MS Following a Clinically Isolated Syndrome
Chard, Declan T.
Dalton, Catherine M.
Swanton, Josephine K.
Fisniku, Leonora K.
Miszkiel, Katherine A.
Thompson, Alan J.
Plant, Gordon T.
Miller, David H.
NEUROLOGY, 2010, 74 (09) : A557 - A558

← 1 2 3 4 5 →